Authors' recommendations: Epidermolysis bullosa is a rare inherited disease. The disease causes blistering, cuts and scarring of the skin which can vary from mild symptoms only, to severe disease causing disability or even death. At the moment there is no cure for epidermolysis bullosa and patients currently use wound care, bandages, and drug treatments to try and reduce the symptoms of the disease. Allantoin is a new drug being developed to treat epidermolysis bullosa. It is applied as a cream once a day over the body. A study is currently looking to see if allantoin can heal wounds and reduce pain and itching. If it is licensed for use in the UK, allantoin will be the first drug specifically available to treat this disease.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/allantoin-zorblisa-for-lesions-associated-with-epidermolysis-bullosa-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)